Biomarkers /
CCND2
Overview
Cyclin D2 (CCND2) is a gene that encodes for a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, missense, nonsense, and silent mutations are observed in cancers such as esophageal cancer, skin cancer, and stomach cancer.
CCND2 is altered in 1.38% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, testicular mixed germ cell tumor, and rectal adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CCND2 are CCND2 Amplification (0.89%), CCND2 Mutation (0.50%), CCND2 Loss (0.08%), CCND2 R262C (0.02%), and CCND2 R165C (0.01%) [3].
Clinical Trials
Significance of CCND2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.